CUMBERLAND PHARMACEUTICALS INC.

Address

2525 WEST END AVE STE 950
NASHVILLE, TN, 37203-1608

Information

DUNS: 069532880
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    Amount: $224,999.00

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of bi ...

    STTRPhase I2016Department of Health and Human Services
  2. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    Amount: $224,910.00

    DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this dise ...

    STTRPhase I2014Department of Health and Human Services
  3. Preclinical Development of a New Drug for Treating Anemia of Chronic Inflammation

    Amount: $246,084.00

    DESCRIPTION (provided by applicant): A strong unmet need exists to develop new treatments for anemias associated with chronic disease states, collectively referred to as anemia of chronic inflammation ...

    STTRPhase I2012Department of Health and Human Services
  4. Radioprotection by use of Topical Lithium Formulations

    Amount: $121,528.00

    DESCRIPTION (provided by applicant): Roughly 500,000 cancer patients are treated with radiotherapy each year. Acute and late sequelae of radiotherapy have a negative impact upon the quality of life of ...

    STTRPhase I2009Department of Health and Human Services
  5. Mannan, A Potential Therapeutic for Asthma

    Amount: $111,805.00

    DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators a ...

    STTRPhase I2009Department of Health and Human Services
  6. High Purity Amphotericin B: A Safer Antimycotic in AIDS

    Amount: $110,644.00

    DESCRIPTION (provided by applicant): Cumberland Pharmaceuticals and the University of Mississippi Mycotic Research Centers' long-term goal will be to improve anti-fungal pharmacotherapy particularly ...

    STTRPhase I2005Department of Health and Human Services
  7. TGF-beta for Pleurodesis

    Amount: $749,143.00

    DESCRIPTION (provided by applicant): Approximately 50,000 cancer patients a year have recurrent fluid accumulation in the space between their chest wall and lung. This condition is called malignant pl ...

    STTRPhase II2004Department of Health and Human Services
  8. TGF-beta for Pleurodesis

    Amount: $749,143.00

    DESCRIPTION (provided by applicant): Approximately 50,000 cancer patients a year have recurrent fluid accumulation in the space between their chest wall and lung. This condition is called malignant pl ...

    SBIRPhase IIDepartment of Health and Human Services
  9. High Purity Amphotericin B: A Safer Antimycotic in AIDS

    Amount: $110,644.00

    DESCRIPTION (provided by applicant): Cumberland Pharmaceuticals and the University of Mississippi Mycotic Research Centers' long-term goal will be to improve anti-fungal pharmacotherapy particularly ...

    SBIRPhase IDepartment of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government